CSF3 and non-Hodgkin lymphoma: A clinical study involved patients with non-Hodgkin’s lymphoma or multiple myeloma showed the combination of plerixafor and G-CSF was superior to G-CSF alone in mobilizing hematopoietic progenitor cells (Flomenberg et al., 2005).